Interstitial Cystitis - Market Insights, Epidemiology and Market Forecast-2027

  • ID: 4330738
  • Drug Pipelines
  • 157 Pages
  • DelveInsight
UP TO OFF
until Dec 31st 2018
1 of 4

FEATURED COMPANIES

  • Aquinox Pharmaceuticals
  • Aspire Pharma
  • Astellas Pharma
  • Boniche Life Sciences Inc
  • Grunenthal
  • Janssen Pharmaceutical
  • MORE

‘Interstitial Cystitis - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Interstitial Cystitis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Interstitial Cystitis from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2016-2027

Interstitial Cystitis - Disease Understanding and Treatment Algorithm

Interstitial Cystitis (IC), also called as Painful Bladder Syndrome, is a chronic condition causing bladder pressure, bladder pain and sometimes pelvic pain. The pain ranges from mild discomfort to severe levels. Bladder is a hollow, muscular organ that stores urine. The bladder expands until it is full and then gives signals to the brain that it is time to urinate, communicating through the pelvic nerves. IC can be of two types: Non-Ulcerative and Ulcerative. However, IC was considered as a rare disease; this comes from a situation of underdiagnosis and misunderstandings about the nature of the IC. It was not until late 1970s, when researchers proved that the vast majority of patients with IC have no Hunner lesions.

The Interstitial Cystitis market report gives the thorough understanding of the Interstitial Cystitis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Interstitial Cystitis in the US, Europe, and Japan.

Interstitial Cystitis Epidemiology

The Interstitial Cystitis epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Prevalent Population, Sex - Specific Prevalent Population, Total Diagnosed Prevalent population, Severity Specific Diagnosed Prevalence] scenario of Interstitial Cystitis in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

estimates suggest higher prevalence of Interstitial Cystitis in the United States with ~4,951,841 prevalent cases in 2016 and ~5,509,338 prevalent cases in 2027. Among the European countries, Germany had the highest prevalent population of Interstitial Cystitis with approximately 843,523 cases, followed by France in 2016. Furthermore, the estimates suggest higher prevalence of the disease among the females throughout the 7MM.

Interstitial Cystitis Drug Chapters

This segment of the Interstitial Cystitis report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The current therapeutic landscape of IC in the US can be divided into two major categories based on the route of administration: Oral Therapies and Intravesical Instillations. Among orally administered therapies, only Elmiron (Pentosan polysulfate sodium; Janssen Pharmaceuticals) is approved by U.S. Food and Drug Administration (FDA) for the treatment of IC. Detailed chapters of upcoming therapies such as Mirabegron (Astellas Pharma), ASP6294 (Astellas Pharma), LP-08 (Lipella Pharmaceuticals) and GRT6010 (Grünenthal) which are expected to launch during the forecast period [2018-2027] have also been covered in the report.

Interstitial Cystitis Market Outlook

The Interstitial Cystitis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According this research, the market size of Interstitial Cystitis in seven major markets is expected to reach USD 5372.71 billion by 2027 from USD 4659.58 billion in 2016. Among the three class therapies (Destructive Therapies, PhotoDynamic Therapies, and Topical Therapies), Destructive Therapy is the most prescribed, that led to highest market size, followed by Topical Therapies. The United States accounts for the largest market size of Interstitial Cystitis in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

Interstitial Cystitis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Expected launch of Mirabegron (Astellas Pharma), ASP6294 (Astellas Pharma), LP-08 (Lipella Pharmaceuticals) and GRT6010 (Grünenthal) in the forecast period [2018-2027] will also create a positive impact on the Interstitial Cystitis market. Out of the above-mentioned therapies, LP-08 (Lipella Pharmaceuticals) holds the highest expectations.

Interstitial Cystitis Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Interstitial Cystitis Report Key Strengths

  • 10 Years Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Key Cross Competition
  • Market Size by Therapies
  • Drugs Uptake

Interstitial Cystitis Report Assessment

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers

Key Benefits:

  • This report will help to develop Business Strategies by understanding the trends shaping and driving Interstitial Cystitis market
  • Organize sales and marketing efforts by identifying the best opportunities for Interstitial Cystitis market
  • To understand the future market competition in the Interstitial Cystitis market.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Aquinox Pharmaceuticals
  • Aspire Pharma
  • Astellas Pharma
  • Boniche Life Sciences Inc
  • Grunenthal
  • Janssen Pharmaceutical
  • MORE
1. Key Insights

2. Interstitial Cystitis: Market Overview at a Glance
2.1. Total Market Share (%) Distribution of Interstitial Cystitis in 2016
2.2. Total Market Share (%) Distribution of Interstitial Cystitis in 2027

3. Interstitial Cystitis (IC): Disease Background and Overview
3.1. Introduction
3.2. Causes
3.3. Risk Factors
3.4. Signs and Symptoms
3.5. Pathophysiology
3.6. Biomarkers for patients with interstitial cystitis
3.7. Diagnosis
3.7.1. Consensus panel recommendations for the evaluation and diagnosis of patients with suspected IC/PBS
3.7.2. American Urology Association diagnosis guideline
3.7.3. Society of Interstitial Cystitis of Japan (SICJ) diagnosis guideline

4. Epidemiology and Patient Population
4.1. Population and Forecast Parameters
4.2. Key Findings

5. 7MM Total Prevalent Patient Population of Interstitial Cystitis

6. 7MM Total Diagnosed Prevalent Patient Population of Interstitial Cystitis

7. Country Wise-Epidemiology of Interstitial Cystitis
7.1. United States
7.1.1. Assumptions and Rationale
7.1.2. Total Prevalent Population of Interstitial Cystitis in the United States
7.1.3. Sex-Specific Prevalent Population of Interstitial Cystitis in the United States
7.1.4. Total Diagnosed Prevalence of Interstitial Cystitis in the United States
7.1.5. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in the United States
7.2. EU5 Countries
7.2.1. Assumptions and Rationale
7.3. Germany
7.3.1. Total Prevalent Population of Interstitial Cystitis in Germany
7.3.2. Sex-Specific Prevalent Population of Interstitial Cystitis in Germany
7.3.3. Total Diagnosed Prevalence of Interstitial Cystitis in Germany
7.3.4. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in Germany
7.4. France
7.4.1. Total Prevalent Population of Interstitial Cystitis in France
7.4.2. Sex-Specific Prevalent Population of Interstitial Cystitis in France
7.4.3. Total Diagnosed Prevalence of Interstitial Cystitis in France
7.4.4. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in France
7.5. Italy
7.5.1. Total Prevalent Population of Interstitial Cystitis in Italy
7.5.2. Sex-Specific Prevalent Population of Interstitial Cystitis in Italy
7.5.3. Total Diagnosed Prevalence of Interstitial Cystitis in Italy
7.5.4. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in Italy
7.6. Spain
7.6.1. Total Prevalent Population of Interstitial Cystitis in Spain
7.6.2. Sex-Specific Prevalent Population of Interstitial Cystitis in Spain
7.6.3. Total Diagnosed Prevalence of Interstitial Cystitis in Spain
7.6.4. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in Spain
7.7. United Kingdom
7.7.1. Total Prevalent Population of Interstitial Cystitis in the United Kingdom
7.7.2. Sex-Specific Prevalent Population of Interstitial Cystitis in the United Kingdom
7.7.3. Total Diagnosed Prevalence of Interstitial Cystitis in the United Kingdom
7.7.4. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in the United Kingdom
7.8. Japan
7.8.1. Assumptions and Rationale
7.8.2. Total Prevalent Population of Interstitial Cystitis in Japan
7.8.3. Sex-Specific Prevalent Population of Interstitial Cystitis in Japan
7.8.4. Total Diagnosed Prevalence of Interstitial Cystitis in Japan
7.8.5. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in Japan

8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Treatment
8.2. Treatment Algorithm
8.2.1. United States
8.2.2. Japan
8.2.3. Europe

9. Unmet Needs

10. Marketed Drugs
10.1. Elmiron: Janssen Pharmaceutical
10.1.1. Drug Description
10.1.2. Mechanism of action
10.1.3. Regulatory Milestones
10.1.4. Advantages & Disadvantages
10.1.5. Safety and Efficacy
10.1.6. Product Profile
10.2. Instillations
10.3. RIMSO-50: Mylan Pharmaceutical
10.3.1. Drug Description
10.3.2. Mechanism of Action
10.3.3. Regulatory Milestones
10.3.4. Advantages & Disadvantages
10.3.5. Safety and Efficacy
10.3.6. Product Profile
10.4. Cystistat: Bioniche Life Sciences Inc
10.4.1. Drug Description
10.4.2. Mechanism of Action
10.4.3. Regulatory Milestones
10.4.4. Advantages & Disadvantages
10.4.5. Safety and Efficacy
10.4.6. Product Profile
10.5. Gepan instill: Pohl-Boskamp GmbH
10.5.1. Drug Description
10.5.2. Mechanism of Action
10.5.3. Advantages & Disadvantages
10.5.4. Safety and Efficacy
10.5.5. Product Profile
10.6. Uracyst: Stellar Pharmaceuticals
10.6.1. Drug Description
10.6.2. Regulatory Milestones
10.6.3. Advantages & Disadvantages
10.6.4. Safety and Efficacy
10.6.5. Product Profile
10.7. Hyacyst: Syner-Med
10.7.1. Drug Description
10.7.2. Advantages & Disadvantages
10.7.3. Safety and Efficacy
10.7.4. Product Profile
10.8. iAluRil: Aspire Pharma
10.8.1. Drug Description
10.8.2. Mechanism of Action
10.8.3. Advantages & Disadvantages
10.8.4. Safety and Efficacy
10.8.5. Product Profile

11. Emerging Therapies
11.1. Key Cross Competition
11.2. AQX-1125: Aquinox Pharmaceuticals
11.2.1. Product Description
11.2.2. Other Developmental Activities
11.2.3. Clinical Development
11.2.4. Safety and Efficacy
11.2.5. Advantages and Disadvantages
11.2.6. Product Profile
11.3. Mirabegron: Astellas Pharma Global Development
11.3.1. Product Description
11.3.2. Other Developmental Activities
11.3.3. Clinical Development
11.3.4. Safety and Efficacy
11.3.5. Advantages and Disadvantages
11.3.6. Product Profile
11.4. ASP6294: Astellas Pharma Global Development
11.4.1. Product Description
11.4.2. Clinical Development
11.4.3. Product Profile
11.5. LP-08: Lipella Pharmaceuticals
11.5.1. Product Description
11.5.2. Other Developmental Activities
11.5.3. Clinical Development
11.5.4. Safety and Efficacy
11.5.5. Product Profile
11.6. GRT6010: Grünenthal
11.6.1. Product Description
11.6.2. Clinical Development
11.6.3. Product Profile

12. Interstitial Cystitis: 7 Major Market Analysis
12.1. Key Findings
12.2. Market Size of Interstitial Cystitis in 7MM

13. The United States Market Outlook
13.1. United States Market Size
13.2. Total Market size of Interstitial Cystitis in the United States
13.3. Market Size by Current Therapies in the United States
13.4. Market Size by Emerging Therapies in the United States

14. EU-5 Countries: Market Outlook
14.1. Germany
14.1.1. Total Market size of Interstitial Cystitis in Germany
14.1.2. Market Size by Current Therapies in Germany
14.1.3. Market Size by Emerging Therapies in Germany
14.2. France
14.2.1. Total Market size of Interstitial Cystitis in France
14.2.2. Market Size by Current Therapies in France
14.2.3. Market Size by Emerging Therapies in France
14.3. Italy
14.3.1. Total Market size of Interstitial Cystitis in Italy
14.3.2. Market Size by Current Therapies in Italy
14.3.3. Market Size by Emerging Therapies in Italy
14.4. Spain
14.4.1. Total Market Size of Interstitial Cystitis in Spain
14.4.2. Market Size by Current Therapies in Spain
14.4.3. Market Size by Emerging Therapies in Spain
14.5. United Kingdom
14.5.1. Total Market size of Interstitial Cystitis in the United Kingdom
14.5.2. Market Size by Current Therapies in the United Kingdom
14.5.3. Market Size by Emerging Therapies in the United Kingdom

15. Japan: Market Outlook
15.1. Total Market size of Interstitial Cystitis in Japan
15.2. Market Size by Current Therapies in Japan
15.3. Market Size by Emerging Therapies in Japan

16. Market Drivers

17. Market Barriers

18. Appendix
18.1. Report Methodology

19. The Publisher Capabilities

20. Disclaimer

21. About the publisher
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Janssen Pharmaceutical
  • Mylan Pharmaceutical
  • Boniche Life Sciences Inc
  • Pohl-Boskamp GmbH
  • Stellar Pharmaceuticals
  • Syner-Med
  • Aspire Pharma
  • Aquinox Pharmaceuticals
  • Astellas Pharma
  • Lipella Pharmaceuticals
  • Grunenthal
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll